Next 10 |
home / stock / itci / itci articles
These mid-cap stocks were the best performers in the last week. Are they in your portfolio? Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% followi...
U.S. stocks were slightly higher, with the Dow Jones index gaining around 0.1% on Tuesday. Shares of Patterson Companies, Inc. (NASDAQ:PDCO) rose s...
Tuesday, Intra-Cellular Therapies Inc (NASDAQ:ITCI) released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy ...
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development ...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the developme...
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) ("Intra-Cellular Therapies"), a biopharmaceutical com...
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall Street...
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial res...
Intra-Cellular Therapies Inc (NASDAQ:ITCI) unveiled on Tuesday topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive thera...
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
2024-06-20 15:00:05 ET Graig Suvannavejh from Mizuho Securities issued a price target of $100.00 for ITCI on 2024-06-20 12:10:00. The adjusted price target was set to $100.00. At the time of the announcement, ITCI was trading at $76.06. The overall price target consensus...
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery- Åsberg Depression Rating Sc...
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Office...